Literature DB >> 2009945

Autologous bone marrow transplantation for non-Hodgkin's lymphoma.

A K McMillan1, A H Goldstone.   

Abstract

Autologous bone marrow transplantation (ABMT) is now so widely applied in the treatment of relapsed high- and intermediate-grade non-Hodgkin's lymphoma (NHL) that it is very important to analyse the evidence on which this practice is based and ask in precise terms what the place of this technique should be. This article will review the data that have been published and discuss the randomised studies now in progress. The possible use of ABMT in other areas such as consolidation of remission and its use in low-grade lymphoma will also be examined. The EBMT data quoted are taken from the 1990 review of the register for ABMT in malignant lymphoma which was presented to the XVIth meeting of the EBMT in the Hague in 1990.

Entities:  

Mesh:

Year:  1991        PMID: 2009945     DOI: 10.1111/j.1600-0609.1991.tb01265.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

Review 1.  The role of autografting in lymphoma.

Authors:  D W Milligan; S G Long
Journal:  Postgrad Med J       Date:  1994-07       Impact factor: 2.401

2.  The use of soybean agglutinin (SBA) for bone marrow (BM) purging and hematopoietic progenitor cell enrichment in clinical bone-marrow transplantation.

Authors:  A Nagler; S Morecki; S Slavin
Journal:  Mol Biotechnol       Date:  1999-04       Impact factor: 2.695

3.  Intracranial haematomas following bone marrow transplantation.

Authors:  S Pomeranz; E Naparstek; E Ashkenazi; A Nagler; A Lossos; S Slavin; R Or
Journal:  J Neurol       Date:  1994-02       Impact factor: 4.849

4.  Frozen vs. nonfrozen bone marrow for autologous transplantation in lymphomas: a report from the Spanish GEL/TAMO Cooperative Group.

Authors:  J Sierra; E Conde; A Iriondo; S Brunet; J Marín; J Pérez de Oteiza; D Caballero; F Martínez; A León; J García-Conde
Journal:  Ann Hematol       Date:  1993-09       Impact factor: 3.673

5.  High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration.

Authors:  P Benedetti Panici; L Pierelli; G Scambia; M L Foddai; M G Salerno; G Menichella; M Vittori; F Maneschi; U Caracussi; R Serafini; G Leone; S Mancuso
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.